Inhibition of TGF-β signaling has been reported to prevent progression and metastasis of certain advanced tumors [15], [16], while TGF-β1 has been shown to reduce the immune response [17], [18] and stimulate angiogenesis [19] in tumor microenvironment. This evidence concerns the gene TGFB1 and neoplasm.